Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26876544 | 0.77 | MMP1 (0.35) | KDM4ETDP1MMP1MMP8CA12 | |
| SCHEMBL21764801 | 0.77 | METAP1 (0.39) | KDM4ETDP1MMP1CA1CA2 | |
| SCHEMBL17346874 | 0.73 | — | — | |
| SCHEMBL411387 | 0.73 | — | — | |
| SCHEMBL9517749 | 0.72 | TSHR (0.35) | KDM4ETDP1MMP1MMP8TSHR | |
| SCHEMBL20078943 | 0.71 | KDM4E (0.44) | KDM4ETDP1CTSAACHEMMP1 | |
| SCHEMBL11882370 | 0.71 | — | — | |
| SCHEMBL28287196 | 0.70 | KDM4E (0.43) | KDM4ETDP1CTSAACHEMMP1 | |
| SCHEMBL21764740 | 0.70 | MAPK1 (0.36) | KDM4ETDP1MMP1MMP8 | |
| SCHEMBL21577324 | 0.70 | KDM4E (0.47) | KDM4ETDP1CTSAACHEMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | KDM4E 3299/4885TDP1 204/4885CTSA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.